Equibles does not estimate personal net worth.
Get an email with a short summary when Rhythm Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get RYTM alertsThe proxy statement of Rhythm Pharmaceuticals, Inc. reports total compensation of $6,118,455 for Yann Mazabraud in fiscal 2025, including a base salary of $557,231. Disclosed compensation is on record for 5 fiscal years. Yann Mazabraud has spoken on 4 earnings calls across 1 company, most recently for Rhythm Pharmaceuticals, Inc. on November 3, 2026. Rhythm Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Rhythm Pharmaceuticals, Inc. includes David P. Meeker, M.D. (CEO and Chairman), Hunter Smith (CEO and CFO), David Meeker (Chairman) and 6 others.
“We are very pleased to have launched IMC-RE4 acquired HO in Japan on October 14th, following approval by the Ministry of Health, Labor and Welfare, or MHLW, and inclusion on Japan's national health insurance drug price list.”
“Our strong international commercial performance continued during the second quarter as the number of patients on IMSivory continues to grow, either through national reimbursements or named patient sales.”
“We are very excited about the EHO opportunity in the international region as we achieved significant milestones and our path towards bringing Just last week, the European Commission granted marketing authorization for MCVRI for the treatment of obesity and control of hunger in patients four years old and older with…”
“We had a strong year in 2025 as our international organization has grown to more than 100 employees across 13 countries.”
Proxy statement
Start not stated–present
Last confirmed April 29, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Rhythm Pharmaceuticals, Inc. (RYTM) | Executive Vice President, Head of International | $557,231 | $6,118,455 |
| 2024 | Rhythm Pharmaceuticals, Inc. (RYTM) | Executive Vice President, Head of International | $467,224 | $5,095,270 |
| 2023 | Rhythm Pharmaceuticals, Inc. (RYTM) | Executive Vice President, Head of International | $448,848 | $1,742,009 |
| 2022 | Rhythm Pharmaceuticals, Inc. (RYTM) | Executive Vice President, Head of International | $380,643 | $1,189,905 |
| 2021 | Rhythm Pharmaceuticals, Inc. (RYTM) | Executive Vice President, Head of International | $384,250 | $2,177,605 |
